Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

A new type of therapy that ‘edits’ a gene in patients with a rare heart condition has been shown to be safe and effective, ...

Boost your inner glow and optimize your output with these IV drips to prep you pre-summer and post-summer shine.

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

Tryptamine Therapeutics advances TRP-8803, an IV psilocin therapy with rapid onset and enhanced safety, to Phase 2 clinical ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Merck (NYSE:MRK) announced Tuesday that a subcutaneously delivered version of its blockbuster cancer therapy pembrolizumab ...

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

Issue discussed at annual meeting of the American Society of Tropical Medicine and Hygiene  ANALYSIS | THE INDEPENDENT & ...